Review article · 2026 · Open access

Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies

Julia Bijoch

Journal of Clinical Medicine, 15(14), 5358 · Published 9 July 2026 · DOI 10.3390/jcm15145358

Open PDFView at the publisherCite this paper

In brief

“Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies” is a 2026 review article by Julia Bijoch, published in Journal of Clinical Medicine. OpenAlex counts 7 citations as of 18 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Clinical Medicine.

Citations
7
Most cited in
2026 (7)
Field-weighted impact
4.59
References
32
Authors
1

Abstract

Incretin-based therapies have transformed the management of obesity and type 2 diabetes mellitus (T2DM). Established agents-the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide-are now widely used, while a diverse pipeline of multi-receptor agents is advancing through late-phase development. GLP-1 receptors are expressed in several oral and other craniofacial tissues, raising the question of how these drugs affect oral health. This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov; January 2010-June 2026) integrates mechanistic studies, randomised controlled trials, pharmacovigilance data, society guidance, and the patient-facing phenomena increasingly raised in the dental chair. Preclinical and limited clinical evidence suggests that GLP-1 RAs may attenuate periodontal inflammation, while their effects on alveolar bone remain uncertain, reflecting both direct receptor and indirect metabolic influences. Concurrently, gastrointestinal adverse effects (nausea, vomiting, belching), reduced fluid intake, and possible salivary changes underlie a cluster of patient-reported complaints colloquially termed "Ozempic mouth", "Ozempic teeth", and "Ozempic breath", alongside the facial soft-tissue changes seen in "Ozempic face". Human oral-health-endpoint data remain scarce; much evidence is preclinical, indirect, or derived from case-level or pharmacovigilance reports. The oral cavity is nonetheless a plausible direct target of incretin pharmacotherapy and a practical monitoring site for tolerability. Dental practitioners should proactively manage the oral consequences of these agents, and validated oral health endpoints should be incorporated into future incretin trials.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bijoch, J. (2026). Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies. Journal of Clinical Medicine, 15(14), 5358. https://doi.org/10.3390/jcm15145358

MLA 9

Bijoch, Julia. “Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.” Journal of Clinical Medicine, vol. 15, no. 14, 2026, p. 5358. https://doi.org/10.3390/jcm15145358.

Chicago

Bijoch, Julia. 2026. “Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.” Journal of Clinical Medicine 15 (14): 5358. https://doi.org/10.3390/jcm15145358.

Harvard

Bijoch, J. (2026) ‘Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies’, Journal of Clinical Medicine, 15(14), p. 5358. doi:10.3390/jcm15145358.

IEEE

J. Bijoch, “Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies,” Journal of Clinical Medicine, vol. 15, no. 14, p. 5358, 2026, doi: 10.3390/jcm15145358.

BibTeX

@article{bijoch2026oral,
  title     = {{Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies}},
  author    = {Bijoch, Julia},
  journal   = {Journal of Clinical Medicine},
  year      = {2026},
  volume    = {15},
  number    = {14},
  pages     = {5358},
  doi       = {10.3390/jcm15145358},
  url       = {https://doi.org/10.3390/jcm15145358}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management

  • GLP-1 receptor agonists
  • incretin-based therapy
  • semaglutide
  • liraglutide
  • tirzepatide
  • oral health
  • periodontal inflammation
  • alveolar bone

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Bijoch, J. (2026). Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies. Journal of Clinical Medicine, 15(14), 5358. https://doi.org/10.3390/jcm15145358

How many times has this paper been cited?

7 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Clinical Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Julia Bijoch.

What is the DOI of this paper?

10.3390/jcm15145358, permanently at https://doi.org/10.3390/jcm15145358. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.